JUMODA: National Prospective and Comparative Study on the Mode of Delivery of Twins

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Completed
CT.gov ID
NCT01987063
Collaborator
(none)
8,979
1
21.9
409.1

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the best obstetrical practices for twin delivery.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Large retrospective cohort studies have reported increased neonatal death and morbidity associated with vaginal delivery in comparison with cesarean in twin pregnancies. A recent large international randomized trial, the Twin Birth Study (TBS), showed that planned cesarean does not significantly decrease or increase the risk of fetal or neonatal death or serious neonatal morbidity, as compared with planned vaginal delivery in twin pregnancy between 32 and 39 weeks of gestation with a first twin in cephalic presentation. However, neither these large retrospective cohort studies, because information regarding delivery management is lacking, nor the TBS, because of insufficient statistical power, can answer the question on how to manage vaginal twin deliveries.

    The aim of the JUMODA study is first to confirm in France whether planned vaginal delivery is not associated with increased neonatal risks in comparison with planned caesarean as shown in the TBS and secondly to determine the best obstetrical practices in case of vaginal delivery.

    Analysis will be performed according to the planned mode of delivery (planned cesarean or planned vaginal delivery) and stratified according to:

    1. Twin rank: second or first twin

    2. Gestational age: before 28 weeks of gestation, before 32 weeks, after 32 weeks, and after 35 weeks

    3. In the whole population and in low risk populations.

    For women delivering vaginally, analysis will be stratified according to:
    1. Second twin presentation: vertex or non vertex

    2. Obstetrical manoeuvres: none, internal cephalic version, external cephalic version, total breech extraction

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    8979 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    National Prospective and Comparative Study on the Mode of Delivery of Twins
    Study Start Date :
    Feb 1, 2014
    Actual Primary Completion Date :
    Jun 1, 2015
    Actual Study Completion Date :
    Dec 1, 2015

    Arms and Interventions

    Arm Intervention/Treatment
    pregnant woman with twins

    pregnant woman with twins

    Outcome Measures

    Primary Outcome Measures

    1. Composite measure of intrapartum and neonatal death and serious morbidity of the second twin after 32 weeks 0 days of gestation [72 hours after birth]

      Intrapartum fetal death Neonatal mortality Apgar score lower than 4 at 5 minutes Neonatal trauma (fracture of long bones or skull, subdural hematoma, brachial plexus elongation, phrenic or facial paralysis, injury of the spinal cord Abnormal level of consciousness (coma, stupor, abnormal response to pain) Intubation longer than 24 hours within the first 72 hours of life, two or more episodes of neonatal convulsions in the first 72 hours of life Proved neonatal infection Bronchopulmonary dysplasia Necrotizing enterocolitis Intraventricular hemorrhage grade III or IV Periventricular leukomalacia.

    Secondary Outcome Measures

    1. Composite measure of intrapartum and neonatal death and serious morbidity of the first twin after 32 weeks 0 days of gestation [Day 28 after birth]

      Composite measure of intrapartum and neonatal death and serious morbidity of the first twin after 32 weeks 0 days of gestation

    2. Composite measure of intrapartum and neonatal death and serious morbidity of the second twin after 32 weeks 0 days of gestation [Day 28 after birth]

      Composite measure of intrapartum and neonatal death and serious morbidity of the second twin after 32 weeks 0 days of gestation

    3. Composite measure of maternal death and serious morbidity after 32 weeks 0 days of gestation [Weeks after birth and before hospital discharge]

      Maternal death Severe postpartum hemorrhage (PPH) defined as PPH requiring transfusion, embolisation, surgery, intensive care unit Pulmonary embolism, deep venous thrombosis Cerebrovascular accident Postpartum psychosis Severe thrombopenia (<50 000) Severe anemia (<7g/dL) Renal failure (oliguria <500 mL/24h or creatinin>135 mmol/L) Maternal transfer in ICU Laparotomy Intraoperative injury to the bowel, ureter or bladder requiring repair Vulvar or perineal hematoma requiring evacuation Third and fourth degree perineal lacerations Systemic infection (positive blood culture or temperature > 38.5 °C on two or more occasions at least 24h apart)

    4. Duration of neonatal hospitalisation of first twin [Weeks after birth and before hospital discharge]

      Duration between birth and hospital discharge

    5. Duration of neonatal hospitalisation of second twin [Weeks after birth and before hospital discharge]

      Duration between birth and hospital discharge

    6. Duration of maternal hospitalisation [Weeks after birth and before hospital discharge]

      Duration between delivery and hospital discharge

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • All patients delivering twins after 22 weeks and 0 days gestation in the participating maternities will be included in the study.
    Exclusion Criteria:
    • Patients who expressed opposition to the use of personal medical data or medical data from their children for this research will not be included in the study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hôpital Robert Debré - APHP Paris France 75019

    Sponsors and Collaborators

    • Assistance Publique - Hôpitaux de Paris

    Investigators

    • Principal Investigator: François GOFFINET, MD, PhD, APHP, France

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Assistance Publique - Hôpitaux de Paris
    ClinicalTrials.gov Identifier:
    NCT01987063
    Other Study ID Numbers:
    • NI12012
    First Posted:
    Nov 19, 2013
    Last Update Posted:
    Apr 19, 2016
    Last Verified:
    Apr 1, 2016

    Study Results

    No Results Posted as of Apr 19, 2016